Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vertex Pharmaceuticals (NQ: VRTX ) 491.62 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Vertex Pharmaceuticals < Previous 1 2 ... 6 7 8 9 10 11 12 13 14 ... 44 45 Next > 3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition January 03, 2024 Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside. Via InvestorPlace January Has Been 1 of the Worst Months for the S&P 500 Over the Last 20 Years. Here Are 3 Stocks to Buy Anyway. January 03, 2024 These stocks are smart picks to buy now, regardless of whether the S&P 500 stocks start off 2024 poorly. Via The Motley Fool Topics Stocks Exposures US Equities 3 Biotech Stocks Set for Breakthroughs in 2024 January 02, 2024 With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. Via InvestorPlace Prediction: These 3 Stocks Will Soar in 2024 January 01, 2024 Investors could enjoy an especially happy new year with these great stocks. Via The Motley Fool 1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024 December 31, 2023 Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name. Via The Motley Fool Decoding Vertex Pharmaceuticals's Options Activity: What's the Big Picture? December 27, 2023 Via Benzinga 3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow December 27, 2023 With a new medicine on the market and plenty of money, Vertex is in great shape. Via The Motley Fool Market Whales and Their Recent Bets on VRTX Options December 22, 2023 Via Benzinga How Is The Market Feeling About Vertex Pharmaceuticals? December 21, 2023 Via Benzinga Want $1 Million in Retirement? Invest $300,000 in These 3 Stocks and Wait a Decade. December 30, 2023 These stocks offer attractive risk-reward profiles. Via The Motley Fool 2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now December 29, 2023 It's been a crazy year across sectors, but winners remain. Via The Motley Fool 3 Monster Stocks to Buy Without Any Hesitation December 27, 2023 These are easy choices for investors seeking market-beating long-term gains. Via The Motley Fool 10 Health Care Stocks With Whale Alerts In Today's Session December 25, 2023 Via Benzinga 3 Top Stocks to Buy Hand Over Fist Before the End of 2023 December 25, 2023 These are ideal stocks to buy sooner rather than later. Via The Motley Fool $1000 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today December 19, 2023 Via Benzinga Editas Just Caught a Break Thanks to Vertex Pharmaceuticals December 23, 2023 Editas isn't out of the woods yet, but it's better off than before. Via The Motley Fool 1 Green Flag and 1 Red Flag for Bluebird Bio Stock December 23, 2023 The stock has been in the news lately. Via The Motley Fool 5 Top Stocks to Buy With Your End-of-the-Year Bonus December 23, 2023 Your bonus could become the gift that keeps on giving. Via The Motley Fool Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock? December 22, 2023 Both develop medicines for rare diseases, and each aims to conquer a niche market. Via The Motley Fool Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock? December 22, 2023 The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction. Via The Motley Fool Exposures Product Safety 3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’ December 21, 2023 It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone." Via InvestorPlace Should you consider NASDAQ:VRTX for quality investing? December 21, 2023 Reasonable Growth, Debt Levels, and a High ROIC Make VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Appealing to Quality Investors. Via Chartmill Is Vertex Pharmaceuticals Sitting on a Gold Mine? December 21, 2023 Vertex shares have climbed about 40% this year. Via The Motley Fool CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief December 20, 2023 The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy. Via InvestorPlace Better Growth Stock: Archer Aviation or Prime Medicine? December 19, 2023 Which of these innovation-themed growth stocks is the better buy? Via The Motley Fool 2 Stocks Profiting From Unstoppable Trends That Could Make You Rich December 18, 2023 It's important to choose companies involved in trends that have long-term potential. Via The Motley Fool CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall? December 16, 2023 The benefits from its first drug launch will trickle in slowly, at least at first. Via The Motley Fool Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip December 16, 2023 This biotech could have more winners on the way. Via The Motley Fool Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development December 15, 2023 These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. Via InvestorPlace Stock Market Rally Surges To 2023 Highs As Fed Pivots Toward Rate Cuts: Weekly Review December 15, 2023 The Dow hit a record high while the S&P 500 and Nasdaq set 2023 bests. Via Investor's Business Daily Topics Economy Stocks Exposures Interest Rates US Equities < Previous 1 2 ... 6 7 8 9 10 11 12 13 14 ... 44 45 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.